Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $63.24 which represents a slight increase of $1.00 or 1.61% from the prior close of $62.24. The stock opened at $62.5 and touched a low ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S.

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...